Article: Dyax Announces Developments in Licensing and Funded Research Program.

LFRP Collaborators Now Report One Approved Product, Fifteen Clinical-Stage Candidates and Dyax Reports Three New Technology License Agreements

CAMBRIDGE, Mass. -- Dyax Corp. (NASDAQ:DYAX) announced today successful advancement into Phase 1 clinical trials of two candidates identified using Dyax's proprietary phage display technology by licensees of the Company's Licensing and Funded Research Program (LFRP).

LFRP licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, recently announced it initiated clinical development for oncology candidate IMC-EB10, ImClone's anti-FLT3 antibody, for the treatment of acute myelogenous leukemia. ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!